1. Home
  2. HEPS vs DSGN Comparison

HEPS vs DSGN Comparison

Compare HEPS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo D-Market Electronic Services & Trading

HEPS

D-Market Electronic Services & Trading

HOLD

Current Price

$2.79

Market Cap

1.0B

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$11.97

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HEPS
DSGN
Founded
2000
2017
Country
Turkey
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
853.8M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
HEPS
DSGN
Price
$2.79
$11.97
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$3.07
$15.25
AVG Volume (30 Days)
289.7K
989.5K
Earning Date
05-07-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$41.29
N/A
Revenue Next Year
$27.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$3.76
52 Week High
$3.30
$17.25

Technical Indicators

Market Signals
Indicator
HEPS
DSGN
Relative Strength Index (RSI) 40.92 38.75
Support Level $2.77 $11.94
Resistance Level $2.91 $13.54
Average True Range (ATR) 0.08 1.16
MACD -0.02 -0.37
Stochastic Oscillator 9.09 0.77

Price Performance

Historical Comparison
HEPS
DSGN

About HEPS D-Market Electronic Services & Trading

D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. It's portfolio offers its retail customers a wide selection of merchandise including electronics and non-electronics (including books, sports, toys, kids and baby products, cosmetics, furniture, etc). The Group derives revenue from the sales of goods, marketplace revenues and other revenues.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: